Key Takeaways
- China lockdowns gutted the quarter: Revenue fell to ₹112 crores (vs ₹150 crores in Q2 FY22) as zero-COVID lockdowns in Shanghai and Guangzhou blocked consignment movement for the key antihistamine therapy, wiping out an estimated ~₹50 crores in sales.
- Margins collapsed on missing high-margin mix: EBITDA margin dropped to 28% in H1 FY23 from 42% a year ago because the products stuck in China and Europe are the company's highest-margin offerings, and the replacements that ran through the plant carried lower profitability.
- Demand is intact, not destroyed: Management insists the order book and demand visibility remain strong for both China and Europe, framing the shortfall as a logistics delay rather than a revenue loss, with finished goods inventory ready to ship the moment ports clear.
- CMO/CDMO pipeline is graduating from promise to purchase orders: The first CMO project received a commercial purchase order after a ~1-year qualification cycle, two more projects are heading to regulatory filing in Q4 FY23, and customer evaluations are expanding to additional products.
- What to watch next quarter: Whether China's zero-COVID policy actually eases enough to unblock ports, the pace at which ~₹50 crores of deferred revenue converts to recognized sales, and any clarity on a revised full-year revenue target.
The China Shock: What Happened and What's at Stake
- Lockdowns froze the supply chain: Continuous lockdowns in Shanghai and Guangzhou, where key distributors are based, prevented import clearance and consignment movement. Even small test shipments were stuck at ports for approximately two months.
- Antihistamine therapy bore the brunt: The antihistamine range is a key therapy for Supriya and China is a key market for it, so the lockdown-driven logistics failure disproportionately hit both the top line and the margin profile.
- The revenue gap is quantifiable: Management pegged the Q2 sales gap from China at roughly ₹50 crores, a figure that explains nearly the entire YoY revenue decline.
- Europe added a smaller, secondary drag: Consignment delays in Europe emerged from the Russia-Ukraine war and energy crisis, with customers facing local clearance issues for importing cargo. The impact was not large as of Q2 but is being watched.
- Recovery timing is genuinely uncertain: Management expects normalization in the coming months but concedes the timeline is outside its control. When pressed on the disconnect between its 1–3 month expectation and macro readings suggesting a longer zero-COVID trajectory, the response was that "only time will tell us."
Ashish Nayak: "I mean it can happen in the coming month; it can happen 3 months down the line. Only time will tell us. That is something which is not in my hands, not in your hands as well."
Margin Mechanics: Why the Drop Was So Sharp
- High-margin products went missing, low-margin ones filled the plant: Gross margin fell from 65% to 58% sequentially because high-margin products destined for China did not ship and were replaced by other products stepping in. Raw material costs and pricing remained constant, so the entire compression is a mix effect.
- Plant stayed busy on less profitable work: Capacity utilization held at 72% despite muted revenue because campaigns planned in the quarter were for products with longer cycle times that are not high contributors to margin or revenue. The plant produced 372 metric tons in H1.
- Expense base rose on structural additions: Power costs, lab expenses, and repairs all increased because the D manufacturing block commissioned in Q1 FY22 is now running at peak capacity. An additional ~₹1.8 crores in IPO expense apportionment also weighed on the comparison.
- The recovery lever is straightforward: When high-margin product demand picks up, those products do not have very long cycle times, so the margin mix can improve relatively quickly once logistics unblock. Finished goods and WIP inventory at ₹106 crores is available to ship quickly.
CMO/CDMO: From Qualification to Commercial Reality
- First purchase order validates the model: The first CMO project, which took approximately one year from initiation, has now received a purchase order for its first commercial supply, qualifying Supriya as a source for the customer.
- Two projects approaching regulatory filing: Two additional CMO projects are expected to cross phase 2 and be ready for regulatory filing in Q4 FY23, marking the next stage of pipeline maturation.
- Customer trust is compounding: The same customer that issued the first PO is already evaluating two more products with Supriya, and the company is receiving new enquiries almost every week with at least half a dozen projects where customers want work to begin.
- Meaningful contribution is a FY24 story: Management does not expect CMO/CDMO contribution to be significant in the next 12 months, but believes it can become a significant contributor after that. Disclosure as a separate line item is promised when activity picks up substantially.
Capacity Build-Out and De-Risking
- E block is the next growth enabler: Construction of the E block with approximately 350 KL reactor capacity is in progress and expected to be operational in Q1 FY24. Once complete alongside other blocks, total capacity will increase to 810 KL.
- Ambernath adds a second site: A new manufacturing block (70 KL) with a pilot plant is being set up at Ambernath attached to the new R&D facility, fully operational in Q1 FY24. This adds a second operating site, directly supporting the de-risking strategy.
- Debottlenecking underway on existing assets: The company is debottlenecking existing manufacturing blocks to increase capacity of running products, extracting more output from current infrastructure.
- Backward integration extends the moat: The backward integration model, which insulates margins from raw material volatility, is being extended to newer products to stay competitive. Raw material pricing remained constant through the quarter.
- New ANDA projects target the US: Five new ANDA projects were initiated in Q2 FY23 across the anesthetic, vitamin, and antihypertensive range, targeting the regulated US market as part of the geographic and product diversification push.
Rajeev Kumar Jain: "We take this challenge as the opportunity to add more products in our basket with improved efficiencies."
Balance Sheet and Capital Allocation
- Receivables improved in absolute terms: Absolute receivables declined by ₹34 crores, though days increased marginally from 68 to 75 due to the lower revenue denominator.
- Inventory built on finished goods ready to ship: Inventory increased to ₹106 crores (261 days) from ₹92 crores (200 days), held at cost. Management characterizes this as finished goods and WIP positioned to quickly commercialize orders if China and Europe situations normalize.
- IPO proceeds largely deployed: ₹60 crores used to repay working capital facilities, ₹13 crores deployed toward the E block (out of ₹92.3 crores allocated), and ₹35 crores utilized for general corporate purposes (out of ₹36 crores allocated).
- Isambe land advance near conversion: An advance of ₹56 crores is expected to be converted to leasehold land in the coming quarter once the agreement is signed.
- Working capital optimization in focus: Management is working to reduce working capital through better coordination between marketing, operations, and procurement.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| China/Europe revenue recovery | Lost H1 sales recovered because demand and order book are intact; only logistics resolution needed | When China lockdowns and Europe uncertainties normalize (no fixed date) |
| CMO projects to regulatory filing | Two CMO projects cross phase 2 and become ready for regulatory filing | Q4 FY23 |
| E block operational | ~350 KL reactor capacity added | Q1 FY24 |
| Ambernath facilities operational | New manufacturing block (70 KL) and pilot plant fully operational | Q1 FY24 |
| Total capacity | Increases to 810 KL once two manufacturing blocks are operational | Q1 FY24 |
| Isambe land conversion | ₹56 crores advance converted to leasehold land | Coming quarter (Q3 FY23) |
| Upgraded ETP facility | Expected completion | Q4 FY23 |
| CMO/CDMO separate disclosure | Contribution disclosed as separate line item | When activity picks up substantially |
| Full-year revenue guidance | Revised guidance provided after watching next couple of months | Towards end of Q3 FY23 |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Operating revenue | ₹112 cr, vs ₹150 cr in Q2 FY22 |
| EBITDA margin | 25%, vs 42% in Q2 FY22 |
| PAT margin | 15% |
| H1 FY23 revenue from operations | ₹213 cr, vs ₹227 cr in H1 FY22 |
| H1 FY23 EBITDA | ₹60 cr, vs ₹96 cr in H1 FY22 |
| H1 FY23 EBITDA margin | 28%, vs 42% in H1 FY22 |
| H1 FY23 PAT | ₹42 cr, 20% of revenue |
| H1 FY23 PBT | ₹58 cr |
| Exports share | ~79% of sales |
| Regulated market share | 22% in H1 FY23, vs 53% in FY22 |
| Gross margin | 58%, down from 65% sequentially |
| Revenue gap from China | ~₹50 cr, for a specific product |
| Capacity utilization | 72% |
| H1 FY23 production volume | 372 metric tons |
| New ANDA projects initiated in Q2 | 5 for anesthetic, 1 for vitamins, 1 for antihypertensive |
| CMO/CDMO projects in regulatory submission stage | 2, expected to file in Q4 FY23 |
| Total capacity once new blocks operational | 810 KL |
| Net working capital | ₹405 cr, vs ₹398 cr |
| Inventory | ₹106 cr, ~261 days vs 200 days as on March 22 |
| Receivables | ₹81 cr, 68 days vs ₹115 cr; decline of ₹34 cr |
| Cash and bank balance | ₹190 cr, of which ₹180 cr in fixed deposits |
| Debt equity | 0.06 |
| IPO expense apportionment in H1 FY23 | ~₹1.8 cr, apportioned over 5 years |
| H1 FY23 power expenses | ₹9.5 cr, vs ₹14 cr for full year FY22 |
| H1 FY23 repairs | ₹8.5 cr, vs ₹7.5 cr in FY22 |